Loading organizations...
Eximis Surgical is a Louisville, Colorado-based medical device company that develops contained specimen removal solutions for minimally invasive surgical procedures. The company's core technology enables healthcare providers in gynecologic oncology and general surgery to safely extract large tissue specimens through small, minimally invasive laparoscopic incisions, mitigating surgical risks and reducing patient recovery times. Operating with fewer than 25 employees, the enterprise has generated $6.1 million in reported revenue while advancing its primary clinical products toward regulatory submission and commercialization. To support these ongoing development efforts, the organization secured $7.5 million in venture capital financing backed by institutional lead investors Questa Capital and Venture Investors. The commercial business was founded prior to 2018 by a team of medical device industry veterans, including Kristin Johnson and Ted Lamson, who previously co-founded NeoTract before its acquisition by Teleflex.
Eximis Surgical has raised $40.0M across 3 funding rounds.
Eximis Surgical has raised $40.0M in total across 3 funding rounds.
Eximis Surgical has raised $40.0M across 3 funding rounds. Most recently, it raised $15.0M Series U in April 2023.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Apr 1, 2023 | $15M Series U | — | Questa Capital, Vensana Capital | Announced |
| Feb 1, 2020 | $17M Series A | — | Questa Capital, Vensana Capital | Announced |
| Nov 1, 2018 | $8M Series U | — | Questa Capital, Vensana Capital | Announced |
Eximis Surgical is a medical device company based in Louisville, Colorado, developing innovative solutions for minimally invasive surgery (MIS), specifically a laparoscopic specimen removal system that enables safe removal of large specimens through small incisions.[1][2][3] The company serves surgeons and healthcare providers in gynecologic oncology and general surgery, addressing the problem of incision enlargement during specimen extraction, which affects up to 2 million patients annually by causing more pain, longer hospital stays, and delayed recovery.[1][2] With recent Series B financing of $8.7 million—including investments from Olympus Innovation Ventures, Questa Capital, and Venture Investors—the company is funding U.S. regulatory activities to bring its fully contained device to market, demonstrating strong growth momentum.[3]
Eximis Surgical emerged to solve a persistent gap in MIS procedures, where even robotic-assisted surgeries through pencil-sized incisions often require extensions up to 7cm for specimen removal.[2][3] Co-founded by Donna Ford-Serbu, who brings 22 years of medical device experience from Covidien and Spectranetics in roles spanning sales, marketing, business development, and strategy, the company has been developing its technology for over five years.[3][4] Early traction includes securing $7.5 million in prior financing led by Questa Capital, with participation from Venture Investors, followed by the recent Series B round that attracted Olympus, a leader in MIS.[1][3] Pivotal moments include validation from gynecologic oncologists and alignment with clinically adopted workflows using specimen bags.[2][3]
Eximis Surgical stands out in the MIS device space through its Laparoscopic Specimen Removal System, designed for:
These features position it as a fast, easy, and safe bridge for the 2 million patients needing better specimen removal options.[2]
Eximis Surgical rides the wave of surging MIS adoption, driven by surgical robotics that have expanded pencil-sized incision procedures over the past decade, yet left specimen removal as a bottleneck requiring larger cuts.[2][3] Timing is ideal amid market forces favoring patient-centric outcomes—like shorter hospital stays and faster recovery—amid rising healthcare costs and demand for contained solutions to prevent complications such as tissue leakage.[3] By enabling true MIS benefits, Eximis influences the ecosystem alongside giants like Olympus, potentially elevating standards in gynecologic oncology and general surgery while supporting regulatory paths for similar innovations.[1][3]
Eximis Surgical is poised for U.S. market entry post-Series B, with funding earmarked for FDA regulatory clearance of its contained removal system.[3] Trends like robotics integration and emphasis on containment will accelerate its trajectory, potentially capturing a slice of the MIS market as incisions stay small for millions.[2] Its influence may grow through partnerships with investors like Olympus, evolving from startup innovator to key enabler of efficient, patient-friendly surgery—ultimately redefining specimen removal as seamlessly as the incisions that precede it.[3]
Eximis Surgical has raised $40.0M in total across 3 funding rounds.
Eximis Surgical's investors include Questa Capital, Vensana Capital.
